Nymox Pharmaceutical Corporation
NYMXF
$0.11
$0.000.09%
OTC PK
| 12/31/2024 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 15.49% | -30.24% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 20.67% | -7.82% | |||
| Operating Income | -20.67% | 7.82% | |||
| Income Before Tax | -19.69% | 6.67% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -19.69% | 6.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.69% | 6.67% | |||
| EBIT | -20.67% | 7.82% | |||
| EBITDA | -20.73% | 7.92% | |||
| EPS Basic | -18.18% | 8.20% | |||
| Normalized Basic EPS | -18.75% | 7.89% | |||
| EPS Diluted | 9.00% | 8.20% | |||
| Normalized Diluted EPS | -18.75% | 7.89% | |||
| Average Basic Shares Outstanding | 0.56% | 0.98% | |||
| Average Diluted Shares Outstanding | 0.56% | 0.98% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||